Please Wait
Applying Filters...
menu
    • menu
    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Zipalertinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Taiho & Cullinan Announce Phase 1/2 Data Published
    Taiho & Cullinan Announce Phase 1/2 Data Published

    01 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/taiho-oncology-and-cullinan-therapeutics-announce-pivotal-rezilient1-phase-12-data-published-in-the-journal-of-clinical-oncology-302470143.html

    PR NEWSWIRE
    01 Jun 2025
    Share Share
    Cullinan, Taiho, and Taiho Oncology to Present Zipalertinib Trial
    Cullinan, Taiho, and Taiho Oncology to Present Zipalertinib Trial

    22 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/22/3087169/0/en/Cullinan-Therapeutics-Taiho-Pharmaceutical-and-Taiho-Oncology-to-Present-Positive-Results-from-Pivotal-Phase-2b-REZILIENT1-Trial-of-Zipalertinib-at-ASCO-2025.html

    GLOBENEWSWIRE
    22 May 2025
    Share Share
    Cullinan to Present Zipalertinib Ph1/2 Data at ASCO Meeting
    Cullinan to Present Zipalertinib Ph1/2 Data at ASCO Meeting

    23 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/23/3066564/0/en/Cullinan-Therapeutics-to-Present-Results-from-REZILIENT1-a-Phase-1-2-Trial-of-Zipalertinib-in-Patients-with-Non-Small-Cell-Lung-Cancer-Harboring-EGFR-Exon-20-Insertion-Mutations-Wh.html

    GLOBENEWSWIRE
    23 Apr 2025
    Share Share
    Taiho & Cullinan Zipalertinib Meets Primary Endpoint In NSCLC Trial
    Taiho & Cullinan Zipalertinib Meets Primary Endpoint In NSCLC Trial

    28 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/taiho-pharmaceutical-taiho-oncology-and-cullinan-therapeutics-announce-primary-endpoint-met-in-phase-2b-trial-of-zipalertinib-in-patients-with-non-small-cell-lung-cancer-harboring-egfr-exon-20-insertion-mutations-who-have-receiv-302362492.html

    PR NEWSWIRE
    28 Jan 2025
    Share Share
    Cullinan's Zipalertinib Shows Positive Pivotal Phase 2b REZILIENT1 Data
    Cullinan's Zipalertinib Shows Positive Pivotal Phase 2b REZILIENT1 Data

    01 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/01/2891804/0/en/Cullinan-Therapeutics-Announces-Positive-Initial-Data-from-Pivotal-Phase-2b-REZILIENT1-Study-of-Zipalertinib.html

    GLOBENEWSWIRE
    01 Jun 2024
    Share Share
    REZILIENT3 Global First-Line Trial of Zipalertinib Launched for NSCLC
    REZILIENT3 Global First-Line Trial of Zipalertinib Launched for NSCLC

    03 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rezilient3-global-first-line-trial-of-zipalertinib-launched-in-patients-with-non-small-cell-lung-cancer-harboring-egfr-exon-20-insertion-mutations-301893051.html

    PR NEWSWIRE
    03 Aug 2023
    Share Share